LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Search

Bio-Techne Corp

Geschlossen

BrancheGesundheitswesen

59.32 -2.29

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

59.02

Max

59.67

Schlüsselkennzahlen

By Trading Economics

Einkommen

56M

38M

Verkäufe

-30M

287M

KGV

Branchendurchschnitt

117.265

105.69

EPS

0.53

Dividendenrendite

0.56

Gewinnspanne

13.326

Angestellte

3,100

EBITDA

71M

78M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+11% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.56%

2.37%

Nächste Dividendenausschüttung

28. Nov. 2025

Nächstes Ex-Dividendendatum

17. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-585M

9B

Vorheriger Eröffnungskurs

61.61

Vorheriger Schlusskurs

59.32

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

Bio-Techne Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

7. Nov. 2025, 22:36 UTC

Ergebnisse

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

Peer-Vergleich

Kursveränderung

Bio-Techne Corp Prognose

Kursziel

By TipRanks

11% Vorteil

12-Monats-Prognose

Durchschnitt 67.43 USD  11%

Hoch 73 USD

Tief 60 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Bio-Techne Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

9 ratings

6

Buy

3

Halten

0

Sell

Technischer Score

By Trading Central

49.67 / 50.24Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Strong Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
help-icon Live chat